Prot #2215-CL-0203: A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible fo

Project: Research project

Project Details

StatusActive
Effective start/end date3/13/233/13/26

Funding

  • Parexel (Prot #2215-CL-0203 // Prot #2215-CL-0203)
  • Astellas Pharma Global Development, Inc. (Prot #2215-CL-0203 // Prot #2215-CL-0203)